|
emtricitabine |
|
Detailed Prescribing Information |
|
July 2006 |
|
Emtriva
=
emtricitabine = FTC Also a component of Truvada, Atripla, Complera, Stribild |
|||
| Forms Available |
200 mg caps 200 mg emtricitabine with 300 mg tenofovir as Truvada 200 mg entricitabine with 600 mg efavirenz and 300 mg tenofovir as Atripla |
||
| Dosing | 200 mg daily | ||
| Renal dosing1 |
Ccr (cc/min) |
Dose (mg) |
|
| > 50 | 200 daily | ||
| 30-49 | 200 q48h | ||
| 15-29 | 200 q72h | ||
| <15 | 200 q96h | ||
| hemodialysis |
200 q96h give dose after dialysis |
||
| Hepatic dosing: insufficient data, but there appears to be no hepatic metabolism | |||
| Food dependence | This medication may be taken with or without food. | ||
| Adverse Effects |
Very well tolerated
Diarrhea,
nausea, rash at incidence similar to other agents Flare of hepatitis B if stopped suddenly. |
||
| Interactions | None significant | ||
| Suggested lab follow-up | None | ||
| Warning |
Rare lactic acidosis
Low barrier to one-step mutational
resistance |
||
| Suggested Usage |
Do not use in combination with
lamivudine,
Truvada,
Epzicom,
Combivir,
Atripla or Trizivir
due to identical mechanism of action (with lamivudine) or duplication of emtricitabine dosing. Emtricitabine has a very low (one-step) barrier to resistance. Always ensure that emtricitabine is used with several potent and active antiretroviral agents. Do not discontinue abruptly in patients with chronic hepatitis B without consideration of continuation of lamivudine or some other agent active against hepatitis B. |
||
|
Complete prescribing information |
http://www.emtriva.com/fpi.pdf | ||
| Links to Antiretroviral Sections |
| Nucleoside & Nucleotide Reverse Transcriptase Inhibitors (NRTI) |
| AZT | ddI | d4T | 3TC | ABC | FTC | TDF ||| Coformulation NRTI: Combivir | Trizivir | Epzicom | Truvada |
| Nonnucleoside Reverse Transcriptase Inhibitors (NNRTI) |
| efavirenz | nevirapine | delavirdine | etravirine | rilpivirine |
| Protease Inhibitors (PI) | Boosted Protease Inhibitors |
| saquinavir | indinavir | ritonavir | nelfinavir | lopinavir + ritonavir | atazanavir | fosamprenavir | tipranavir |
| Co-receptor Inhibitors |
| maraviroc |
| Fusion Inhibitors |
| enfuvirtide |
| Integrase Inhibitors |
| raltegravir | elvitegravir |
| Antiretroviral Metabolic Inhibitors |
| cobicistat | ritonavir |
| Coformulations |
| Atripla (efavirenz/tenofovir/emtricitabine) | Complera (rilpivirine/tenofovir/emtricitabine) | Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine) |
3/27/2013
1. Renal dosing information from: Ian R.
McNicholl & Rudolph A. Rodriguez, MD, Dosing of Antiretroviral Drugs in Renal
Insufficiency and Hemodialysis, May 2004
http://hivinsite.ucsf.edu/InSite?page=md-rr-18